Clinical Trials Browser

Phase 4 × Melanoma × Nivolumab × Clear all

NCT07459543 2026-03-09

A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India

Phase 4 Not yet recruiting

Melanoma, Skin Neoplasms

NCT06116461 2024-04-22

NIVOPTIMIZE

Phase 4 Recruiting

Melanoma

NCT03313544 2023-04-21

Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1

Phase 4 Unknown

DermatologicThoracic

Lung Neoplasms, Melanoma